Trial Profile
A phase II, open and multi center study of nimotuzumab concurrent with intensity modulated radiation therapy in recurrent nasopharyngeal carcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2022
Price :
$35
*
At a glance
- Drugs Nimotuzumab (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- 07 Nov 2022 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last verified September 2018).
- 30 Sep 2016 Status changed from not yet recruiting to active, no longer recruiting.
- 02 Jun 2014 New trial record